Obicetrapib
Based on 1 Customer Validation
Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 866399-87-3
- Formula: C32H31F9N4O5
- Molecular Weight:722.60
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
Lipid Metabolism Compound Library
HY-L091
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Biological Activity
|
apoB |
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 866399-87-3
-
Appearance Solid
-
Molecular Weight 722.60
-
Formula C32H31F9N4O5
-
Color White to light yellow
-
SMILES
FC(F)(F)C1=CC(C(F)(F)F)=CC(CN(C2=NC=C(OCCCC(O)=O)C=N2)[C@@H]3C4=CC(C(F)(F)F)=CC=C4N([C@@H](C3)CC)C(OCC)=O)=C1
-
Synonyms
TA-8995; DEZ-001; AMG-899
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : ≥ 100 mg/mL (138.39 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3839 mL | 6.9195 mL | 13.8389 mL | 34.5973 mL |
| 5 mM | 0.2768 mL | 1.3839 mL | 2.7678 mL | 6.9195 mL | |
| 10 mM | 0.1384 mL | 0.6919 mL | 1.3839 mL | 3.4597 mL | |
| 15 mM | 0.0923 mL | 0.4613 mL | 0.9226 mL | 2.3065 mL | |
| 20 mM | 0.0692 mL | 0.3460 mL | 0.6919 mL | 1.7299 mL | |
| 25 mM | 0.0554 mL | 0.2768 mL | 0.5536 mL | 1.3839 mL | |
| 30 mM | 0.0461 mL | 0.2306 mL | 0.4613 mL | 1.1532 mL | |
| 40 mM | 0.0346 mL | 0.1730 mL | 0.3460 mL | 0.8649 mL | |
| 50 mM | 0.0277 mL | 0.1384 mL | 0.2768 mL | 0.6919 mL | |
| 60 mM | 0.0231 mL | 0.1153 mL | 0.2306 mL | 0.5766 mL | |
| 80 mM | 0.0173 mL | 0.0865 mL | 0.1730 mL | 0.4325 mL | |
| 100 mM | 0.0138 mL | 0.0692 mL | 0.1384 mL | 0.3460 mL |
Obicetrapib Related Classifications
HY-18778 Related Classifications
Powered by Bioz
- Obicetrapib
- 866399-87-3
- TA-8995
- DEZ-001
- AMG-899
- TA8995
- TA 8995
- DEZ001
- DEZ 001
- DEZ-001
- AMG899
- AMG 899
- AMG-899
- CETP
- Apolipoprotein
- LPL Receptor
- LDLR
- very low-density lipoprotein
- high-density lipoprotein
- dyslipidemia
- low-density lipoprotein
- apolipoprotein B
- cholesteryl esters
- cholesteryl ester transfer protein
- atherosclerotic cardiovascular disease
- triglycerides
- Inhibitor
- inhibitor
- inhibit